What DESTINY-Breast04 did in 2022 wasn't just approve a new drug — it created a new patient population. Before trastuzumab deruxtecan, "HER2-low" wasn't a treatment category; IHC 1+ and IHC 2+/ISH-negative tumors were classified as HER2-negative and treated accordingly. Suddenly, more than half of HR+/HER2-negative patients had a targetable designation. That's roughly 350,000 patients per year in the US alone who now have a treatment option they didn't have three years ago. That's the scale of change happening in breast cancer research, and it's happening across subtypes simultaneously — ADC sequencing in HER2+, de-escalation trials for early-stage disease, and mRNA vaccines moving into Phase 3 adjuvant TNBC. This is the most consequential period in breast cancer drug development since trastuzumab itself.
This article is for informational purposes only and does not constitute medical advice. Clinical trial eligibility and availability vary. Always consult a qualified healthcare professional before making any medical decisions or considering participation in a clinical trial.
Summary
Breast cancer is the most commonly diagnosed cancer globally, and the 2026 trial landscape reflects its molecular complexity — with fundamentally different treatment strategies for HR+/HER2−, HER2+, HER2-low, and triple-negative subtypes. Antibody-drug conjugates have transformed outcomes in HER2-low (DESTINY-Breast04: PFS 9.9 vs. 5.1 months vs. chemotherapy) and TNBC (ASCENT: PFS 5.6 vs. 1.7 months), and are now being tested in earlier treatment lines. PARP inhibitors, CDK4/6 inhibitors, AKT pathway agents, and oral SERDs are all being refined in active Phase 2/3 trials. Patients searching for trials in 2026 need their tumor molecular profile — ER/PR/HER2 status, HER2-low designation, BRCA1/2, PIK3CA, PD-L1 CPS — before starting.
ClinicalMetric Analysis
- Pre-2022 diagnoses may need pathology re-review for HER2-low status. Trastuzumab deruxtecan is approved for HER2-low (IHC 1+ or IHC 2+/ISH-) but hospitals didn't routinely record that subclassification before DESTINY-Breast04 changed the landscape. If you were diagnosed with HR+/HER2-negative before 2022 and have progressed on CDK4/6 inhibitors, requesting a HER2-low reassessment on archived tumor tissue may unlock eligibility for trials or approved therapies previously ruled out.
- CAPItello-291's benefit was narrower than the headline suggests. Capivasertib plus fulvestrant showed 7.3 vs. 3.1 month PFS in the PIK3CA/AKT1/PTEN-altered subgroup — impressive. In the overall population, PFS was 7.2 vs. 3.6 months. Mutation testing is required before assuming eligibility; a patient without a qualifying alteration gets a smaller signal and more toxicity. Knowing your PIK3CA/PTEN status is the prerequisite for this entire treatment category.
- De-escalation trials in early HER2+ are systematically underenrolled. Trials like ATEMPT and KAITLIN test whether patients can safely receive less chemotherapy or fewer drugs in adjuvant HER2+ disease. They're hard to fill because oncologists — and understandably, patients — fear undertreatment more than overtreatment. But the accumulating data on T-DM1 and pertuzumab toxicity in low-risk early-stage disease suggests we're overtreating a meaningful subset. The framing matters: de-escalation trials aren't asking you to get less care; they're asking whether a different regimen produces the same survival with fewer long-term effects.
HR+/HER2− Breast Cancer: CDK4/6 Resistance and What Comes Next
Hormone receptor-positive, HER2-negative breast cancer accounts for roughly 70% of all breast cancer diagnoses. CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with endocrine therapy are now standard of care in metastatic HR+ disease, having demonstrated overall survival benefit — most compellingly ribociclib plus letrozole in MONALEESA-2 (OS 63.9 vs. 51.4 months) and abemaciclib in MONARCH-2 and MONARCH-3. Most patients eventually develop resistance, and what happens next is the central question driving 2026 HR+ trials.
The PI3K/AKT pathway is the most validated resistance mechanism. Capivasertib (AZD5363, AstraZeneca), an AKT inhibitor, received FDA approval in 2023 in combination with fulvestrant for PIK3CA/AKT1/PTEN-altered HR+/HER2− metastatic breast cancer after CDK4/6 inhibitor progression — showing PFS improvement of 7.3 vs. 3.1 months versus fulvestrant alone in the CAPItello-291 trial. Trials are now testing capivasertib in earlier treatment lines. Elacestrant (oral SERD, Orion/Menarini), the first approved oral selective estrogen receptor degrader, showed PFS benefit over standard endocrine therapy in ESR1-mutated disease (EMERALD trial: median PFS 3.8 vs. 1.9 months) and is being studied in combination with CDK4/6 inhibitors in Phase 3 trials.
- Next-generation CDK2/4/6 inhibitors addressing palbociclib-resistant disease (CDK4/6 amplification as resistance mechanism)
- Capivasertib in first-line PIK3CA-mutated disease — CAPItello-291 data now being extended to earlier settings
- Elacestrant combinations with CDK4/6 inhibitors — Phase 3 ELEVATE trial ongoing
- T-DXd (trastuzumab deruxtecan) in HER2-low HR+ disease — DESTINY-Breast06 reading out in 2026
HER2+ Breast Cancer: De-escalation and the ADC Era
HER2-positive breast cancer has undergone the most dramatic outcome improvement of any breast cancer subtype since trastuzumab approval in 1998. Early-stage HER2+ disease is now highly curable: the KATHERINE trial showed that T-DM1 (trastuzumab emtansine) as adjuvant therapy after residual disease post-neoadjuvant treatment reduced invasive disease-free survival events by 50% versus trastuzumab alone. The current trial focus has shifted toward two questions: who can receive less treatment without compromising cure rates, and how to sequence ADCs optimally in metastatic disease.
De-escalation trials (ADAPT, PHERGain, COMPASS-HER2) are identifying genomic and pathological markers that predict patients who can be cured with HER2-directed therapy alone, sparing them from chemotherapy toxicity. Trastuzumab deruxtecan (Enhertu) transformed the metastatic HER2+ landscape in DESTINY-Breast03 — PFS 28.8 months versus T-DM1's 6.8 months, an unprecedented separation — and is now being studied as neoadjuvant therapy in early-stage HER2+ disease. HER2-directed bispecific antibodies (zanidatamab, targeting HER2 and HER3 simultaneously) and CAR-T cell approaches are in Phase 1/2.
Triple-Negative Breast Cancer: From Worst Prognosis to Active Pipeline
TNBC — ER-negative, PR-negative, HER2-negative — was historically the subtype with the worst prognosis and fewest treatment options. That has changed significantly since 2020. Three major breakthroughs have restructured TNBC treatment:
- Immunotherapy: Pembrolizumab plus chemotherapy (KEYNOTE-522) is now standard neoadjuvant therapy for Stage II/III TNBC regardless of PD-L1 status, showing pathological complete response rate of 64.8% vs. 51.2% with chemotherapy alone and improved event-free survival. For metastatic disease, pembrolizumab plus chemotherapy is standard for PD-L1 CPS ≥10 (atezolizumab's approval was withdrawn after IMpassion130 successor trial failure).
- Sacituzumab govitecan (Trodelvy, Gilead): TROP2-directed ADC delivering SN-38. ASCENT Phase 3 showed PFS 5.6 vs. 1.7 months and OS 12.1 vs. 6.7 months versus single-agent chemotherapy in metastatic TNBC. Now being tested in the neoadjuvant and adjuvant settings in patients with residual disease after standard therapy.
- PARP inhibitors in BRCA-mutated TNBC: Olaparib and talazoparib for germline BRCA1/2-mutated disease. OlympiAD (olaparib) and EMBRACA (talazoparib) both showed PFS benefit of approximately 3 months versus chemotherapy. Combination PARP inhibitor plus immunotherapy trials are actively recruiting — the hypothesis being that PARP inhibition increases tumor mutational burden and PD-L1 expression, potentially sensitizing BRCA-mutated TNBC to checkpoint inhibitors.
- mRNA-4157/V940 adjuvant vaccine (Moderna/Merck): Personalized neoantigen vaccine plus pembrolizumab in Phase 3 for high-risk TNBC and HR+ breast cancer with residual disease after neoadjuvant therapy. After the 44% reduction in melanoma recurrence data, the breast cancer Phase 3 (mRNA-4157-P201) is among the most watched trials of 2026.
Biomarkers You Need Before Searching for Trials
The molecular complexity of breast cancer means that "breast cancer trial" is an almost meaningless search category without your specific biomarker profile. Before investing time in trial identification, you need:
- ER/PR/HER2 status: The foundational classification. HER2 IHC and ISH results — including whether you're HER2-low (IHC 1+ or 2+/ISH-) — are required for ADC trial eligibility.
- BRCA1/2 germline testing: Required for PARP inhibitor trial eligibility. Germline blood test, not just somatic tumor testing — both are needed if you're considering combination trials.
- PIK3CA mutation status: Activating mutations in PIK3CA (found in ~40% of HR+ breast cancers) predict response to capivasertib and alpelisib. Tumor tissue or liquid biopsy.
- PD-L1 CPS: For metastatic TNBC and some HR+ trials. CPS ≥10 is required for some pembrolizumab indications; CPS ≥1 for others.
- ESR1 mutation status: For elacestrant and next-generation SERD trials in HR+ disease that progressed on aromatase inhibitors. Liquid biopsy is preferred (ESR1 mutations emerge under treatment pressure and may not be in archival tissue).
Comprehensive genomic profiling (Foundation One CDx, Tempus xT) covers most of this in a single test. For liquid biopsy specifically, Guardant360 captures ESR1 mutations and PIK3CA mutations from circulating tumor DNA. Many trials will provide or reimburse required testing at screening — ask the trial coordinator before paying out of pocket.